These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12900142)

  • 1. The effect of heterogeneity on optimal regimens in cancer chemotherapy.
    Murray JM; Coldman AJ
    Math Biosci; 2003 Sep; 185(1):73-87. PubMed ID: 12900142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle.
    Murray JM
    Math Biosci; 1994 Oct; 123(2):183-213. PubMed ID: 7827419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal chemotherapy regimens: influence of tumours on normal cells and several toxicity constraints.
    Matveev AS; Savkin AV
    IMA J Math Appl Med Biol; 2001 Mar; 18(1):25-40. PubMed ID: 11339336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mathematical model of cancer chemotherapy with an optimal selection of parameters.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1990 May; 99(2):205-30. PubMed ID: 2134520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.
    Marcu LG; Bezak E
    J Theor Biol; 2012 Mar; 297():41-7. PubMed ID: 22182756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic failure of antineoplastic agents. Extracellular and cellular causes].
    Hofsli E
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):37-40. PubMed ID: 2000585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
    Batmani Y; Khaloozadeh H
    Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.
    Luu KT; Boni J
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):697-708. PubMed ID: 27491482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.
    Denduluri N; Patt DA; Wang Y; Bhor M; Li X; Favret AM; Morrow PK; Barron RL; Asmar L; Saravanan S; Li Y; Garcia J; Lyman GH
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1383-93. PubMed ID: 26553767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy and cancer cure.
    Bertino JR
    Int J Radiat Oncol Biol Phys; 1982 Jan; 8(1):109-13. PubMed ID: 7061245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of chemotherapy in advanced non-small cell lung cancer.
    Lustberg MB; Edelman MJ
    Curr Treat Options Oncol; 2007 Feb; 8(1):38-46. PubMed ID: 17634834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Algorithms for scheduling of chemotherapy plans.
    Sevinc S; Sanli UA; Goker E
    Comput Biol Med; 2013 Dec; 43(12):2103-9. PubMed ID: 24290927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management system of cancer chemotherapy regimens].
    Ichiki T; Uramoto H; Shinohara Y; Kitagawa N; Hara Y; Kinoshita T; Ushio T; Eto S; Tsukada J; Takahashi K
    J UOEH; 2008 Mar; 30(1):47-54. PubMed ID: 18350752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential chemotherapy and circadian rhythm in human solid tumours. A randomised trial.
    Focan C
    Cancer Chemother Pharmacol; 1979; 3(3):197-202. PubMed ID: 393429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.